These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 20145632)

  • 21. Schizophrenia: moving beyond monoamine antagonists.
    Conn PJ; Tamminga C; Schoepp DD; Lindsley C
    Mol Interv; 2008 Apr; 8(2):99-107. PubMed ID: 18403654
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of a novel M4 muscarinic positive allosteric modulator on behavior and cognitive deficits relevant to Alzheimer's disease and schizophrenia in rhesus monkey.
    Lange HS; Vardigan JD; Cannon CE; Puri V; Henze DA; Uslaner JM
    Neuropharmacology; 2021 Oct; 197():108754. PubMed ID: 34389398
    [TBL] [Abstract][Full Text] [Related]  

  • 23. M4 agonists/5HT7 antagonists with potential as antischizophrenic drugs: serominic compounds.
    Suckling CJ; Murphy JA; Khalaf AI; Zhou SZ; Lizos DE; van Nhien AN; Yasumatsu H; McVie A; Young LC; McCraw C; Waterman PG; Morris BJ; Pratt JA; Harvey AL
    Bioorg Med Chem Lett; 2007 May; 17(9):2649-55. PubMed ID: 17317171
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synthesis and structure-activity relationships of allosteric potentiators of the m(4) muscarinic acetylcholine receptor.
    Kennedy JP; Bridges TM; Gentry PR; Brogan JT; Kane AS; Jones CK; Brady AE; Shirey JK; Conn PJ; Lindsley CW
    ChemMedChem; 2009 Oct; 4(10):1600-7. PubMed ID: 19705385
    [No Abstract]   [Full Text] [Related]  

  • 25. Identification of N-substituted 8-azatetrahydroquinolone derivatives as selective and orally active M(1) and M(4) muscarinic acetylcholine receptors agonists.
    Takai K; Inoue Y; Konishi Y; Suwa A; Uruno Y; Matsuda H; Nakako T; Sakai M; Nishikawa H; Hashimoto G; Enomoto T; Kitamura A; Uematsu Y; Kiyoshi A; Sumiyoshi T
    Bioorg Med Chem Lett; 2013 Aug; 23(16):4644-7. PubMed ID: 23816371
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of a radioligand, [(3)H]LY2119620, to probe the human M(2) and M(4) muscarinic receptor allosteric binding sites.
    Schober DA; Croy CH; Xiao H; Christopoulos A; Felder CC
    Mol Pharmacol; 2014 Jul; 86(1):116-23. PubMed ID: 24807966
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 3-Aminomethyl Derivatives of 2-Phenylimidazo[1,2-a]-pyridine as Positive Allosteric Modulators of GABA
    Marcinkowska M; Kołaczkowski M; Kamiński K; Bucki A; Pawłowski M; Siwek A; Karcz T; Starowicz G; Słoczyńska K; Pękala E; Wesołowska A; Samochowiec J; Mierzejewski P; Bienkowski P
    ACS Chem Neurosci; 2017 Jun; 8(6):1291-1298. PubMed ID: 28211669
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clozapine interaction with the M2 and M4 subtypes of muscarinic receptors.
    Michal P; Lysíková M; El-Fakahany EE; Tucek S
    Eur J Pharmacol; 1999 Jul; 376(1-2):119-25. PubMed ID: 10440097
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Positive allosteric modulators of the metabotropic glutamate receptor 2 for the treatment of schizophrenia.
    Fraley ME
    Expert Opin Ther Pat; 2009 Sep; 19(9):1259-75. PubMed ID: 19552508
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Detection and quantification of allosteric modulation of endogenous m4 muscarinic acetylcholine receptor using impedance-based label-free technology in a neuronal cell line.
    Chen AN; Malone DT; Pabreja K; Sexton PM; Christopoulos A; Canals M
    J Biomol Screen; 2015 Jun; 20(5):646-54. PubMed ID: 25534830
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery and Development of Muscarinic Acetylcholine M
    Takai K; Enomoto T
    Chem Pharm Bull (Tokyo); 2018; 66(1):37-44. PubMed ID: 29311510
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Selective activation of muscarinic acetylcholine receptors for the treatment of schizophrenia.
    Dean B
    Curr Pharm Biotechnol; 2012 Jun; 13(8):1563-71. PubMed ID: 22283751
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Positive Allosteric Modulation of the Muscarinic M1 Receptor Improves Efficacy of Antipsychotics in Mouse Glutamatergic Deficit Models of Behavior.
    Choy KH; Shackleford DM; Malone DT; Mistry SN; Patil RT; Scammells PJ; Langmead CJ; Pantelis C; Sexton PM; Lane JR; Christopoulos A
    J Pharmacol Exp Ther; 2016 Nov; 359(2):354-365. PubMed ID: 27630144
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discovery of a selective M₄ positive allosteric modulator based on the 3-amino-thieno[2,3-b]pyridine-2-carboxamide scaffold: development of ML253, a potent and brain penetrant compound that is active in a preclinical model of schizophrenia.
    Le U; Melancon BJ; Bridges TM; Vinson PN; Utley TJ; Lamsal A; Rodriguez AL; Venable D; Sheffler DJ; Jones CK; Blobaum AL; Wood MR; Daniels JS; Conn PJ; Niswender CM; Lindsley CW; Hopkins CR
    Bioorg Med Chem Lett; 2013 Jan; 23(1):346-50. PubMed ID: 23177787
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthesis and pharmacological evaluation of M4 muscarinic receptor positive allosteric modulators derived from VU10004.
    Huynh T; Valant C; Crosby IT; Sexton PM; Christopoulos A; Capuano B
    ACS Chem Neurosci; 2015 Jun; 6(6):838-44. PubMed ID: 25857219
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery of a novel 2,4-dimethylquinoline-6-carboxamide M
    Long MF; Engers JL; Chang S; Zhan X; Weiner RL; Luscombe VB; Rodriguez AL; Cho HP; Niswender CM; Bridges TM; Conn PJ; Engers DW; Lindsley CW
    Bioorg Med Chem Lett; 2017 Nov; 27(22):4999-5001. PubMed ID: 29037946
    [TBL] [Abstract][Full Text] [Related]  

  • 37. State-dependent alterations in sleep/wake architecture elicited by the M4 PAM VU0467154 - Relation to antipsychotic-like drug effects.
    Gould RW; Nedelcovych MT; Gong X; Tsai E; Bubser M; Bridges TM; Wood MR; Duggan ME; Brandon NJ; Dunlop J; Wood MW; Ivarsson M; Noetzel MJ; Daniels JS; Niswender CM; Lindsley CW; Conn PJ; Jones CK
    Neuropharmacology; 2016 Mar; 102():244-53. PubMed ID: 26617071
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Muscarinic M1 and M4 receptors: Hypothesis driven drug development for schizophrenia.
    Dean B; Scarr E
    Psychiatry Res; 2020 Jun; 288():112989. PubMed ID: 32315882
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multi-Target Approach for Drug Discovery against Schizophrenia.
    Kondej M; Stępnicki P; Kaczor AA
    Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30309037
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The muscarinic receptor antagonist tropicamide suppresses tremulous jaw movements in a rodent model of parkinsonian tremor: possible role of M4 receptors.
    Betz AJ; McLaughlin PJ; Burgos M; Weber SM; Salamone JD
    Psychopharmacology (Berl); 2007 Oct; 194(3):347-59. PubMed ID: 17594079
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.